How gene therapy could rewrite the future of Huntington’s patients

September 26, 2025

For the first time, doctors have successfully treated Huntington’s disease, one of the most devastating inherited conditions in the world. The breakthrough marks a watershed moment in medicine, offering hope to families who have long faced the disease’s inevitable decline.

Huntington’s disease, which runs in families, progressively kills brain cells. Its symptoms resemble a cruel combination of dementia, Parkinson’s, and motor neurone disease. Patients typically begin showing signs in their thirties or forties, with the condition almost always proving fatal within two decades.

Now, scientists say they have managed to slow the disease’s progression by an unprecedented 75 per cent. A team in the United Kingdom that contributed to an international trial told the BBC that what normally amounts to one year of decline in a patient could now take four years, potentially giving patients decades of improved quality of life.

Professor Sarah Tabrizi, director of the University College London Huntington’s Disease Centre, described the results as “spectacular”. She admitted, “We never in our wildest dreams would have expected a 75 per cent slowing of clinical progression.”
The impact is already visible. One patient who had been medically retired has returned to work. Others in the trial, who were predicted to require wheelchairs, are still walking. While the names of those treated have not been disclosed, the findings are being hailed as a turning point in the battle against Huntington’s.

How the Treatment Works

The therapy is a form of gene-based medicine delivered in a single dose within 12 to 18 hours of a carefully controlled brain procedure. Its goal is to permanently lower levels of the toxic huntingtin protein, which is responsible for destroying neurons in Huntington’s patients.

The disease is caused by a genetic error in the huntingtin gene. If one parent has Huntington’s, there is a 50 per cent chance the child will inherit the faulty gene. Instead of producing a normal protein essential for brain function, the mutation causes the huntingtin protein to become toxic, attacking the very cells it is meant to support.

The new therapy combines gene therapy with gene silencing technology. It begins with a harmless virus that has been engineered to carry a specially designed sequence of DNA. Once delivered into brain cells, the new DNA becomes active, switching off the harmful protein and reducing its levels in the brain.Prof Tabrizi compared the virus to a microscopic postman, delivering the vital genetic instructions where they are needed most. Early results suggest this approach could fundamentally alter how Huntington’s is treated in the future.

A Costly but Promising Path

While the promise is immense, researchers have cautioned that the therapy will likely come with a high price tag. Cutting-edge genetic treatments are among the most expensive in modern medicine, raising questions about how accessible such therapies will be if approved for wider use.

Nevertheless, scientists argue that the potential to dramatically slow or even prevent a disease once thought untreatable outweighs the challenges. Prof Tabrizi called the volunteers who participated in the trial “truly brave” and said she was “overjoyed for the patients and families”.

Looking Ahead

The research is now moving into a new phase. Scientists are preparing to test the therapy on people at “stage zero” Huntington’s—those who carry the defective gene but have not yet developed symptoms. The aim is to see whether the disease can be delayed significantly or even prevented altogether.

If successful, this would mean that people who once faced a near-certain future of neurological decline could instead live long, healthy lives. For now, the first results are being greeted with both excitement and cautious optimism. The therapy represents not only a milestone for Huntington’s patients but also a demonstration of what modern genetic medicine may achieve in tackling other neurodegenerative conditions.

“This is the beginning,” Prof Tabrizi said, predicting that gene therapy will open the door to treatments for many more people.
For families who have lived under the shadow of Huntington’s, the breakthrough offers something that has long seemed impossible: genuine hope.